Troubleshooting Biomarker Development Strategies

In this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical development and optimisation of biomarker development strategies. Vercruysse discusses biomarker development strategies, which are of great importance for every clinical trial – he identifies the critical success factors, the optimum time to start biomarker development and how it is decided which clini...
To continue reading this story get free access